(19)
(11)EP 3 260 130 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
07.02.2018 Bulletin 2018/06

(43)Date of publication A2:
27.12.2017 Bulletin 2017/52

(21)Application number: 17181410.6

(22)Date of filing:  03.11.2010
(51)Int. Cl.: 
A61K 38/18  (2006.01)
A61K 38/00  (2006.01)
C07K 14/71  (2006.01)
C07K 14/495  (2006.01)
A61K 39/00  (2006.01)
A61P 1/16  (2006.01)
A61K 38/17  (2006.01)
C07K 16/28  (2006.01)
A61K 47/68  (2017.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 03.11.2009 US 280544 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
10829042.0 / 2496247

(71)Applicant: Acceleron Pharma Inc.
Cambridge, MA 02139 (US)

(72)Inventors:
  • KONCAREVIC,, Alan
    Boston, MA Massachusetts 02215 (US)
  • LACHEY,, Jennifer
    Arlington, MA Massachusetts 02474 (US)
  • SEEHRA,, Jasbir
    Lexington, MA Massachusetts 02421-6818 (US)
  • SHERMAN,, Matthew, L.
    Newton, MA Massachusetts 02459 (US)

(74)Representative: Evenson, Jane Harriet et al
Mathys & Squire LLP The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)

  


(54)METHODS FOR TREATING FATTY LIVER DISEASE


(57) In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signalling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.